Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Graft-versus-host disease in allogeneic bone marrow transplantation: the role of monoclonal antibodies in prevention and treatment
Autore:
Hiscott, A; McLellan, DS;
Indirizzi:
Publ Hlth Lab Serv, Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England Publ Hlth Lab Serv Salisbury Wilts England SP4 0JG P4 0JG, Wilts, England Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth, Hants, England Univ Portsmouth Portsmouth Hants England Sci, Portsmouth, Hants, England
Titolo Testata:
BRITISH JOURNAL OF BIOMEDICAL SCIENCE
fascicolo: 2, volume: 57, anno: 2000,
pagine: 163 - 169
SICI:
0967-4845(2000)57:2<163:GDIABM>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC MYELOGENOUS LEUKEMIA; SEVERE APLASTIC-ANEMIA; A-CHAIN IMMUNOTOXIN; T-CELL DEPLETION; CAMPATH-1 ANTIBODIES; SIBLING DONORS; INCREASED RISK; CYCLOSPORINE; LYMPHOCYTES; PHASE;
Keywords:
antibodies, monoclonal; bone marrow transplantation; Graft vs host disease;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
60
Recensione:
Indirizzi per estratti:
Indirizzo: Hiscott, A Publ Hlth Lab Serv, Ctr Appl Microbiol & Res, Porton Down, Salisbury SP4 0JG, Wilts, England Publ Hlth Lab Serv Porton Down Salisbury Wilts England SP4 0JG
Citazione:
A. Hiscott e D.S. McLellan, "Graft-versus-host disease in allogeneic bone marrow transplantation: the role of monoclonal antibodies in prevention and treatment", BR J BIOMED, 57(2), 2000, pp. 163-169

Abstract

Reconstitution of an individual's haemopoietic stem cells by bone marrow transplantation (BMT) is the recommended treatment for a number of haematological conditions, both malignant and non-malignant. Despite evolution in BMT technology over the past forty years, graft-versus-host disease (GvHD) remains a major, potentially lethal complication. GvHD normally affects the skin, liver and gastrointestinal tract, resulting in a high rate of morbidity. The standard prophylaxis for GvHD is a combination of methotrexate and cyclosporin A, but this is only partially effective. Acute GvHD is difficultto treat and many patients are resistant to steroid therapy. Alternative methods of prevention and treatment are now being sought, and include monoclonal antibodies (MAbs) which target T cells and cytokines. T-cell depletionof donor marrow using rat MAbs reduces the incidence of GvHD but can increase the chances of leukaemic relapse. Mouse MAbs also have been used but some produce severe side-effects. The most successful MAbs are those linked to toxins, and these immunotoxins (IT) have proved very effective in reversing steroid-resistant acute GvHD. MAb therapies are becoming increasingly important in the treatment and prevention of GvHD, and could replace steroidsas the main treatment option in some situations. It is predicted that, ultimately peripheral blood stem-cell transplantation will replace the use of BMT; however, this alternative stem-cell source will not remove the GvHD risks associated with allogeneic stem-cell transplantation. Therefore, reducing the risks will remain a major challenge in the successful allogeneic transplantation of haemopoeitic stem cells for the foreseeable future.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 09:17:05